Ultragenyx Pharmaceutical (RARE) Q4 2025 earnings summary

Executive summary

• Achieved 20% year-over-year revenue growth in 2025, reaching $673 million, driven by strong commercial execution across four marketed products in over 35 countries, with notable growth in Crysvita and Evkeeza sales.

• Strategic restructuring implemented, including a 10% workforce reduction (~130 employees), to align resources, reduce expenses, and target profitability by 2027.

• Two potential product approvals (MPS IIIA and GSDIa) and pivotal Angelman syndrome data expected in 2026, marking it as a pivotal year.

Financial highlights

• 2025 total revenue reached $673 million, exceeding guidance; Crysvita contributed $481 million (17% growth), Dojolvi $96 million (9% growth), Evkeeza $59 million (84% growth), and Mepsevii $37 million.

• Fourth quarter 2025 revenue was $207 million, up 25% compared to Q4 2024.

• Net loss for 2025 was $575 million, or $5.83 per share.

• Year-end cash, cash equivalents, and marketable securities totaled $738 million.

• Operating expenses for 2025 were $1.2 billion, including $153 million in non-cash stock-based compensation.

Outlook and guidance

• 2026 revenue guidance set at $730–$760 million, representing 8–13% growth, excluding new launches.

• Crysvita revenue expected at $500–$520 million; Dojolvi at $100–$110 million.

• Combined R&D and SG&A expenses in 2026 projected to be flat to down low single digits versus 2025; 2027 combined expenses expected to decrease at least 15% from 2025.

• Path to profitability in 2027 relies on continued double-digit growth from existing products, contributions from new launches, and monetization of two PRVs.